A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway

• Main Authors: Sae-Bom Yoon (Author), Hyowon Hong (Author), Hee-Jong Lim (Author), Ji Hye Choi (Author), Yoon Pyo Choi (Author), Seong Wook Seo (Author), Hyuk Woo Lee (Author), Chong Hak Chae (Author), Woo-Kyu Park (Author), Hyun Young Kim (Author), Daeyoung Jeong (Author), Tran Quang De (Author), Chang-Seon Myung (Author), Heeyeong Cho (Author)
• Format: Book
• Published: Elsevier, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Interleukin-1 receptor-associated kinase 4 (IRAK4) is a pivotal enzyme in the Toll-like receptor (TLR)/MYD88 dependent signaling pathway, which is highly activated in rheumatoid arthritis tissues and activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL). Inflammatory responses followed by...